journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/29771279/peri-operative-therapy-for-operable-gastroesophageal-adenocarcinoma-past-present-and-future
#1
V Aggelis, D Cunningham, F Lordick, E C Smyth
Surgery represents the only chance of cure for patients with gastroesophageal adenocarcinoma; however surgery alone does not cure most patients. Over the past decade, several multimodality adjunctive treatments have improved survival for patients with operable gastroesophageal adenocarcinoma who are undergoing surgical resection; these include peri-operative chemotherapy, neoadjuvant chemoradiotherapy, adjuvant chemotherapy and adjuvant chemoradiotherapy. More recently, the results of several large randomised trials are leading to a shift in the peri-operative treatment of gastroesophageal cancer, away from anthracycline-based and towards taxane-based chemotherapy regimens...
May 16, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29767693/neoadjuvant-score-in-locally-advancer-rectal-cancer-integrating-downstaging-in-risk-assessment-and-looking-for-new-valuable-end-points
#2
S Roselló, A Cervantes
No abstract text is available yet for this article.
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29767688/safety-and-dose-modification-for-patients-receiving-niraparib
#3
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten, J Ledermann, M Pineda, S Ellard, J Sehouli, A Gonzalez-Martin, D Berton-Rigaud, R Madry, A Reinthaller, S Hazard, W Guo, M R Mirza
Background: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the United States and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In the pivotal ENGOT-OV16/NOVA trial, the dose reduction rate due to TEAE was 68.9%, and the discontinuation rate due to TEAE was 14.7%, including 3.3% due to thrombocytopenia. A retrospective analysis was performed to identify clinical parameters that predict dose reductions...
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29767677/randomized-phase-3-study-of-docetaxel-plus-bavituximab-in-previously-treated-advanced-non-squamous-non-small-cell-lung-cancer
#4
D E Gerber, L Horn, M Boyer, R Sanborn, R Natale, R Palmero, P Bidoli, I Bondarenko, P Germonpre, D Ghizdavescu, A Kotsakis, H Lena, G Losonczy, K Park, W-C Su, M Tang, J Lai, N L Kallinteris, J S Shan, M Reck, D R Spigel
Background: Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an anti-tumor immune response. This phase 3 trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Patients and Methods: Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding...
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29767670/treatment-of-the-myeloid-lymphoid-neoplasm-with-fgfr1-rearrangement-with-fgfr1-inhibitor
#5
S Verstovsek, V Subbiah, L Masarova, C C Yin, G Tang, T Manshouri, E Asatiani, N G Daver
No abstract text is available yet for this article.
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29750420/latest-clinical-evidence-and-further-development-of-parp-inhibitors-in-ovarian-cancer
#6
M R Mirza, S Pignata, J A Ledermann
Background: For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of anti-angiogenic strategies given with chemotherapy and in the maintenance setting. In the past decade, numerous poly(ADP-ribose) polymerase (PARP)-inhibiting agents have been assessed. Design: We review key trials that have led to the approval of three PARP inhibitors - olaparib, niraparib and rucaparib - as maintenance therapy for platinum-sensitive recurrent ovarian cancer...
May 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29750418/yang-dd-krasnova-a-nead-kt-et-al-androgen-deprivation-therapy-and-risk-of-rheumatoid-arthritis-in-patients-with-localized-prostate-cancer
#7
Vincenza Conteduca, Ugo De Giorgi, Gianfranco Lauletta
No abstract text is available yet for this article.
May 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741568/hemophagocytic-lymphohistiocytosis-associated-with-dabrafenib-and-trametinib-combination-therapy-following-pembrolizumab-administration-for-advanced-melanoma
#8
K Sasaki, J Uehara, S Iinuma, H Doi, M Honma, Y Toki, A Ishida-Yamamoto
No abstract text is available yet for this article.
May 7, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741566/circulating-tumor-cell-increase-as-a-biomarker-of-disease-progression-in-metastatic-castration-resistant-prostate-cancer-patients-with-low-baseline-ctc-counts
#9
D Lorente, D Olmos, J Mateo, D Dolling, D Bianchini, G Seed, P Flohr, M Crespo, I Figueiredo, S Miranda, H I Scher, L W M M Terstappen, J S de Bono
Background: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumor cell counts (BLCTCs)<5/7.5 mL represent a good prognosis subgroup, but are non-evaluable for response assessment (decrease in CTCs). The aim of the study is to determine the value of any increase in CTCs (CTC Progression) as an indicator of progression in prostate cancer patients with low pre-treatment CTCs (<5)...
May 7, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741578/management-of-infusion-reactions-to-systemic-anticancer-therapy-esmo-clinical-practice-guidelines
#10
S Roselló, I Blasco, L García Fabregat, A Cervantes, K Jordan
No abstract text is available yet for this article.
May 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741577/cervical-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#11
C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, N Colombo
No abstract text is available yet for this article.
May 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741569/activity-and-safety-of-crizotinib-in-patients-with-advanced-clear-cell-sarcoma-with-met-alterations-european-organization-for-research-and-treatment-of-cancer-phase-ii-trial-90101-create
#12
P Schöffski, A Wozniak, S Stacchiotti, P Rutkowski, J-Y Blay, L H Lindner, S J Strauss, A Anthoney, F Duffaud, S Richter, V Grünwald, M G Leahy, P Reichardt, J Sufliarsky, W T van der Graaf, R Sciot, M Debiec-Rychter, T van Cann, S Marréaud, M Lia, T Raveloarivahy, L Collette, S Bauer
No abstract text is available yet for this article.
May 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29741565/rectal-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#13
R Glynne-Jones, L Wyrwicz, E Tiret, G Brown, C Rödel, A Cervantes, D Arnold
No abstract text is available yet for this article.
May 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29733336/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st-gallen-international-expert-consensus-conference-on-the-primary-therapy-of-early-breast-cancer-2017
#14
G Curigliano, H J Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, M M Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann
No abstract text is available yet for this article.
May 3, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29726923/a-phase-1-dose-escalation-and-dose-expansion-study-of-brontictuzumab-in-subjects-with-selected-solid-tumors
#15
R Ferrarotto, G Eckhardt, A Patnaik, P LoRusso, L Faoro, J V Heymach, A M Kapoun, L Xu, P Munster
Background: Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, immunogenicity and preliminary efficacy of brontictuzumab in patients with solid tumors. Patients ans Methods: Subjects with selected refractory solid tumors were elegible. Brontictuzumab was administered intravenously at various dose levels and schedule during dose escalation, and at 1...
May 3, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29722791/phase-3-safety-study-of-intravenous-nepa-a-novel-fixed-antiemetic-combination-of-fosnetupitant-and-palonosetron-in-patients-receiving-highly-emetogenic-chemotherapy
#16
L Schwartzberg, E Roeland, Z Andric, D Kowalski, J Radic, D Voisin, G Rizzi, R Navari, R J Gralla, Meinolf Karthaus
Background: NEPA, an oral fixed combination of the NK1RA netupitant (300mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50mg), is the first fixed antiemetic combination to have been approved. A single oral NEPA capsule plus dexamethasone (DEX) given prior to AC and non-AC highly emetogenic chemotherapy (HEC) showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) over PALO plus DEX for 5 days post-chemotherapy. The safety of NEPA was well-established in the Phase 2/3 clinical program in 1169 NEPA-treated patients...
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29722789/the-importance-of-jointly-analyzing-treatment-administration-and-toxicity-associated-with-targeted-therapies-a-case-study-of-regorafenib-in-soft-tissue-sarcoma-patients
#17
M Longué, B Cabarrou, J Wallet, T Brodowicz, H Roché, J M Boher, J P Delord, N Penel, T Filleron
Background: Different methods have been proposed to analyze adverse events (AEs) associated with targeted therapies. While these AEs lead to dose adjustments for many patients, conventional reporting methods do not take drug administration into consideration. This paper underlines the importance of jointly reporting AEs and drug administration using prevalence, and proposes a complementary approach to reporting. Patients and methods: The prevalence method estimates the probability of progression-free patients being in a particular health state (State 1: AEs with full dose, State 2: AEs with reduced dose, State 3: no AEs with reduced dose) at different time points...
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29722787/divergent-adaptation-in-thyroid-cancers
#18
A Sottoriva
No abstract text is available yet for this article.
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29718120/mapping-unmet-supportive-care-needs-quality-of-life-perceptions-and-current-symptoms-in-cancer-survivors-across-the-asia-pacific-region-results-from-the-international-step-study
#19
A Molassiotis, P Yates, Q Li, W K W So, K Pongthavornkamol, P Pittayapan, H Komatsu, M Thandar, M Yi, S Titus Chacko, V Lopez, J Butcon, D Wyld, R J Chan
No abstract text is available yet for this article.
April 30, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29718117/capturing-intra-tumor-genetic-heterogeneity-by-de-novo-mutation-profiling-of-circulating-cell-free-tumor-dna-a-proof-of-principle
#20
L De Mattos-Arruda, B Weigelt, J Cortes, H H Won, C K Y Ng, P Nuciforo, F-C Bidard, C Aura, C Saura, V Peg, S Piscuoglio, M Oliveira, Y Smolders, P Patel, L Norton, J Tabernero, M F Berger, J Seoane, J S Reis-Filho
No abstract text is available yet for this article.
April 30, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"